Biopharmaceutical entrepreneurship in two Japanese and French bioclusters: differences in founder profiles and experience
Favoured by genetic engineering breakthroughs, a new type of firm has emerged in the pharmaceutical industry. New Biotechnology Firms (NBFs) are ‘bridging institutions', accelerating the commercialisation of science from academia to the pharmaceutical market and facilitating technological incursions into drug development or therapeutic paths yet unexplored. As such, they have raised industrial and political interest around the world. Successes can be outstanding and some countries seem to offer much more favourable environments than others. Countries' performances are usually benchmarked against their provision of favourable resources and institutions, but this article takes an alternative route by considering the entrepreneurial side of NBF as a major factor in their emergence. ‘Entrepreneur biographies' and firm creation experience were collected in two comparable bioclusters in France (Evry) and Japan (Kobe), on 11 Japanese and French drug development NBFs. The result shows an interesting variation in backgrounds and motivations, in that almost all our French entrepreneurs came from public research institutes, whereas a large share of the Japanese entrepreneurs came from large pharmaceutical companies. This finding questions the universal nature of entrepreneurship in biopharmaceutical firms and invites consideration for a model of entrepreneurship that is socially embedded in a country's specific institutional and historical factors.
|Date of creation:||2009|
|Date of revision:|
|Publication status:||Published in Asian Business & Management, 2009, 8 (4), pp.429-460|
|Note:||View the original document on HAL open archive server: https://halshs.archives-ouvertes.fr/halshs-00424901|
|Contact details of provider:|| Web page: https://hal.archives-ouvertes.fr/|
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Samuel Kortum & Josh Lerner, 2000. "Assessing the Contribution of Venture Capital to Innovation," RAND Journal of Economics, The RAND Corporation, vol. 31(4), pages 674-692, Winter.
- Mangematin, Vincent & Lemarie, Stephane & Boissin, Jean-Pierre & Catherine, David & Corolleur, Frederic & Coronini, Roger & Trommetter, Michel, 2003.
"Development of SMEs and heterogeneity of trajectories: the case of biotechnology in France,"
Elsevier, vol. 32(4), pages 621-638, April.
- Vincent Mangematin & Stéphane Lemarié & Jean-Pierre Boissin & David Catherine & Frédéric Corolleur & Roger Coronini & Michel Trommetter, 2003. "Development of SMEs and heterogeneity of trajectories: the case of biotechnology in France," Grenoble Ecole de Management (Post-Print) hal-00422563, HAL.
- Casamatta, Catherine, 2002.
"Financing and Advising: Optimal Financial Contracts with Venture Capitalists,"
CEPR Discussion Papers
3475, C.E.P.R. Discussion Papers.
- Catherine Casamatta, 2003. "Financing and Advising: Optimal Financial Contracts with Venture Capitalists," Journal of Finance, American Finance Association, vol. 58(5), pages 2059-2086, October.
- Galambos, Louis & Sturchio, Jeffrey L., 1998. "Pharmaceutical Firms and the Transition to Biotechnology: A Study in Strategic Innovation," Business History Review, Cambridge University Press, vol. 72(02), pages 250-278, June.
When requesting a correction, please mention this item's handle: RePEc:hal:journl:halshs-00424901. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (CCSD)
If references are entirely missing, you can add them using this form.